Open Access

Ginsenoside Re: Its chemistry, metabolism and pharmacokinetics

Chinese Medicine20127:2

https://doi.org/10.1186/1749-8546-7-2

Received: 21 July 2011

Accepted: 7 February 2012

Published: 7 February 2012

Abstract

Ginsenosides, the bioactive components of ginseng, can be divided into two major groups, namely 20(S)-protopanaxatriol (e.g. Re, Rg1, Rg2, and Rb3) and 20(S)-protopanaxadiol (e.g. Rb1, Rb2, Rc, and Rd). Biological and environmental factors may affect the content of ginsenosides in different parts of ginseng plant. Evidence from pharmacokinetic and metabolic studies of Re demonstrated that (1) the absorption of Re is fast in gastrointestinal tract; (2) Re may be metabolized mainly to Rh1 and F1 by intestinal microflora before absorption into blood; and (3) Re is quickly cleared from the body.

Background

Ginseng is a key herb in Chinese medicine, and has a wide range of therapeutic and pharmacological uses [13]. Panax ginseng is a slow growing perennial herb of the Araliaceae family usually cultivated in China, Japan, Korea and Russia, as well as in the United States and Canada. Ginseng root has been used as an oriental folk medicine for several thousand years [2, 4]. It is a highly valued medicinal plant in the Far East that and also popular in the West in the past 20 years [2, 47].

A number of studies suggest that both Panax ginseng C.A. Meyer (also known as Asian ginseng, Chinese ginseng or Korea ginseng) and Panax quinquefolius (also known as American ginseng) have multiple components and pharmacological functions [714]. Among the complex constituents of ginseng, ginsenosides (also known as ginseng saponins or triterpene saponins) are the major components responsible for biochemical and pharmacological actions of ginseng [9, 1517]. With the development of modern technology, more than 150 naturally occurring ginsenosides have been isolated from Panax species [18]. About 40 ginsenosides have been identified from the root of Panax ginseng [1, 1922].

In order to explore the pharmacological actions, mechanisms and clinical applications of ginseng, some researchers focused on purified individual ginsenosides rather than whole ginseng extracts [1, 23]. Individual ginsenosides may have different characteristics in chemistry, metabolism, and pharmacokinetics. Ginsenoside Re (Re) belongs to 20(S)-protopanaxatriol group (Figure 1), and is a major ginsenoside in ginseng [7, 10, 16, 22, 2427]. Literature shows that Re exhibits multiple pharmacological activities via different mechanisms [12, 16, 28]. For example, in cardiovascular system, Re possesses negative effects on cardiac contractility and autorhythmicity, anti-arrhythmic and anti-ischemic effects, angiogenic regeneration activities and cardiac electrophysiological functions [28]. Xie et al. and Li et al. [13, 2932] found that the quantity of Re in ginseng leaf and berry is much higher than in ginseng main root and suggested that ginseng leaf-stem could be a valuable source for Re. There have been other new findings in recent years. This article provides an overview of the recent advances in chemistry, metabolism and pharmacokinetics of Re.
Figure 1

Chemical structure of ginsenoside Re (MW = 946).

Chemistry and content

Chemical structure of Re

Rg1, Rc, Rd, Re, Rb1, Rb2 and Rb0 are the main ginsenosides in quantity [1, 33]. The top six major ginsenosides (Rb1, Re, Rd, Rc, Rg1 and Rb3) make up over 70% of total ginsenoside content in P. quinquefolius [34, 35].

Ginsenosides are the glycosides that contain aglycone with dammarane (except Ro). Ginsenosides (Figure 2) are generally divided into two groups, namely the protopanaxadiol (PPD) and protopanaxatriol (PPT) ginsenoside groups. The sugar moities in the PPD group including Rb1, Rb2, Rc, Rd, Rg3 and Rh3, attach to the 3-position of dammarane-type triterpine, whereas the sugar moities in the PPT group including Re, Rf, Rg1, Rg2 and Rh1, attach to the 6-position of dammarane-type triterpine. A ginsenoside possesses a rigid four trans-ring steroid skeleton with a modified side chain at C-20 [1, 17, 3639]. The chemical structures of ginsenosides are different from each other in the number, linkage position and type of sugar [17, 39]. During extraction, sugar moieties of ginsenosides may be cleaved by acid hydrolysis or endogenous glycosidases to give corresponding aglycones [25, 36]. PPD and PPT may rearrange into panaxadiol and panaxatriol, respectively, to provide artificial ginsenoside products. Kang et al. [40] showed that PPD and PPT ginsenoside groups had different bioactivities, even opposite effects. Recently, Zhu et al. [41] found six new PPT-type ginsenosides extracted from the P. ginseng root, named Re1 to Re6 (compounds 1-6) respectively, along with ten other known PPT ginsenosides.
Figure 2

Chemical structures of protopanaxadiol (A) and protopanaxatriol (B).

Content of Re in ginseng

The biological and environmental factors that may affect the quantity and quality of ginsenosides in ginseng [14, 35] include the species, age, part of the plant, season of harvest, method of cultivation, and means of preservation. For example, the content of Re, Rg1 and Rd is higher in the wild P. ginseng roots than in the cultivated ginseng roots, while the content of Rc, Rb2 and Rb1 is lower in the wild P. ginseng roots than in the cultivated ones. These differences in content of ginsenosides might affect their biological and pharmacological properties. Root ginsenoside content depends on the age of ginseng plant. For example, the plants younger than four years of age are considered unsuitable for harvest due to their low ginsenoside content [35, 4244]. Lim et al. [35] determined the genotypes and environmental factors affecting the ginsenoside content among eight wild populations of P. quinquefolius. The influence of genotypes and environment on ginsenoside content varies among different types of ginsenosides. Specifically, the Re content varies with populations but not locations, whereas Rb1, Rc and Rb2 only varies with locations, and Rg1 and Rd varies with both. Ginsenoside levels are decreased, while ginseng growth is increased, at an intensively managed garden location. The content and composition of ginsenosides vary with other environmental conditions such as the type of soil, temperature, light intensity and water content [45].

Using high pressure microwave-assisted extraction (HPMAE) and high-performance liquid chromatography (HPLC) coupled with evaporative light scattering detection (ELSD), i.e. HPMAE HPLC-ELSD, Qu et al. [46] studied the effects of different parts and age of P. quinquefolius on the content of 12 ginsenosides, namely Rg1, Re, Rf, Rg2, Rh1, Rb1, Rc, Rb2, Rb3, Rd, Rh2 and F11. The study ranked the parts of five-years-old P. quinquefolius in terms of total content of these 12 ginsenosides in a descending order: leaf, root-hair, rhizome, main root and stem, suggesting that the leaf could be a better source for ginsenosides, as compared with other parts of ginseng plant. It also found that in ginseng roots, the content of Re and Rb1, the major ginsenosides, increase with age of the plant.

In a comparative study on the quality of Tongrentang Red Ginseng and Korean Red Ginseng, Wu et al [47] found that the content of Re, Rg1 and Rb1 in the Tongrentang Red Ginseng is less than the content in the Korean Red Ginseng.

Another extensive study [48] performed a quantitative analysis of Re, Rb1 and Rg1 in P. quinquefolius berry and flower sampled in various months throughout the year, by enzyme-linked immunosorbent assay (ELISA). The P. quinquefolius flower had higher content of Re, Rb1 and Rg1 and the lowest content of Re in the berries harvested in September [48]. To analyze the Re content in P. quinquefolius berry pulp extracts, Morinaga et al. [49] performed a new Eastern blot technique with anti-Re monoclonal antibody, and confirmed that the content of Re varies from part to part in the plant.

Lee et al. [50] reported the variations in the ginsenoside profiles of ginseng landraces in Korea. They found that the P. ginseng wild population exhibits three types of ginsenoside profiles affected by genetic and environmental factors.

Metabolism and pharmacokinetics

Re has recently been studied extensively [12, 13, 30]; however, little is known about the metabolic and pharmacokinetic profiles.

Absorption

After oral administration, Re is in contact with the gastriointestinal fluids containing gastric acids and gastric enzymes, intestinal enzymes, and colonic bacteria [51, 52]. Li et al. [23, 53] studied the pharmacokinetic parameters and absolute bioavailability of Re, R1, Rg1, Rd, and Rb1 after oral or intravenous administration of total notoginsenosides. Main pharmacokinetic parameters of these constituents were determined by Drug and Statistics (DAS) for Windows pharmacokinetics software. The results showed that Re, R1, Rg1, Rd and Rb1 reached peak concentration in plasma within about 45 minutes after oral administration of total panax notoginsenoside (TPNG) powder in rats, suggesting a rapid absorption of ginsenosides in gastrointestinal tract. The absolute bioavailability of Re was 7.06% [53]. To confirm the rapid absorption finding, Joo et al. [27] conducted a pharmacokinetic study using ICR mice and ultra performance liquid chromatography-electrospray ionization-mass spectrometry (UPLC-ESI-MS) analytical method. This pharmacokinetic study [27] revealed that the time to reach the peak plasma concentration after oral administration was 0.4 ± 0.2 hour. The data also showed that the oral bioavailability was 0.19-0.28%. Qi et al. [54] found that the oral bioavailability of PPD ginsenosides (Ra3, Rb1, Rd, Rg3 and Rh2) and PPT ginsenosides (Rg1, Re, Rh1, and R1) was less than 5% and PPT ginsenosides had better bioavailability, possibly due to the faster degradation of PPD ginsenosides.

Metabolism and biotransformation

Han et al. [55] showed that PPT ginsenosides are hydrolyzable to Rh1 under mild acidic conditions. Tabaw et al. [56] found that two degradation products of the PPT ginsenosides, Rh1 and F1 could reach the systemic circulation in humans in addition to compound-K resulting from the stepwise deglycosylation of PPD ginsenosides. Bae et al. [57] further confirmed that the PPT (Re and Rg1) could be metabolized mainly to Rh1 and G-F1 in the gastrointestinal tract by intestinal microflora, before absorption into the blood. Chi and Ji et al. [58] tested the biotransformation of Re and Rb1 by cell extracts from various food-grade edible microorganisms. As shown in Figure 3, Re was transformed into Rh1 via Rg2 by Bif. sp. Int57 and Bif. sp. SJ32; A. niger transformed Re into Rh1 via Rg1; A. usamii transformed Re into Rg2. However, Rb1 was transformed into compound-K and Rh1 by different pathways [58].
Figure 3

Proposed possible metabolism pathway of G-Re by stomach acidity and large intestine bacteria.

Metabolic research of Re in animals was also reported [59]. Six SD rats were used and divided into three groups. Feces were collected at 12, 24, 36, 48 and 60 hours after oral administration of Re (100mg/kg). Six metabolites of Re were detected in the feces of rat. The structures of the metabolites were identified as 20(S)-ginsenoside Rg2, 20(S)-ginsenoside Rh1, 20(R)-ginsenoside Rh1, ginsenoside F1, 3-oxo-ginsenoside Rh1 and PPT. The metabolic pathways of Re in animals were similar to those in humans [59].

A similar metabolic study was also carried out in vivo with HPLC coupled with electrospray ionization and quadrupole time-of-flight tandem mass spectrometry (HPLC-ESI-TOF-MS/MS) [60]. The rat urine samples were collected and pretreated through C(18) solid-phase extraction cartridges prior to analysis. As a result, eleven and nine metabolites together with Re were detected and identified in rat urine after oral and intravenous administration, respectively. Oxidation and deglycosylation were found to be the major metabolic processes of the constituent in rat, indicating that a large part of the intact ginsenosides was metabolized and transformed to ginsenosides with more biological effects in the gastrointestinal tract [52]. PPT ginsenosides, such as Re and Rg1, were mainly converted to Rh1 and F1 and then to corresponding aglycones [51, 56].

Elimination

Xia et al. [38] applied a developed and validated liquid chromatography-electrospray ionization-mass spectrometry (LC-ESI-MS) method to detect Re, Rg1, Rd, Rb1 and ophiopogonin D in rat plasma. Re and Rg1 were eliminated quickly from the body. The pharmacokinetic behaviors of Rd and Rb1 were significantly different from those of Re and Rg1 in rat. Joo et al. [27] found that Re was rapidly cleared from the body within 0.2 ± 0.03 hour for male mice and 0.5 ± 0.08 hour for female mice after intravenous administration. They also found that ginseng berry extract exhibited a superior oral absorption of Re as compared to orally fed Re, suggesting that ginseng berry extract may be of choice for Re intake [27].

The plasma concentrations of Re and Rg1 were determined and the pharmacokinetic parameters were calculated after intravenous Shenmai injection in ten volunteers [61]. The study found the distribution and elimination of Re and Rg1 to be rapid after intravenous injection; and the pharmacokinetic characteristics could be fitted to the two-compartment model of pharmacokinetics.

Conclusion

Multiple biological and environmental factors affect the quantity and quality of ginsenosides in ginseng parts. Studies on Re demonstrate that (1) the absorption of Re is quick in rats; (2) PPT, Re and Rg1, are likely to be metabolized to Rh1 and F1 by intestinal microflora before absorption into the blood; and (3) Re can be quickly eliminated from the body.

Abbreviations

DAS: 

Drug and Statistics for Windows pharmacokinetic software

ELISA: 

enzyme-linked immunosorbent assay

Re: 

ginsenoside Re (Rg1, Rg2, Rg3, Rf, Rb1, Rb2, Rb3, Rc, Rd, and Re1 - Re6 are the same abbreviations with Re)

HPLC-ESI-TOF-MS/MS: 

high-performance liquid chromatography coupled with electrospray ionization and quadrupole time-of-flight tandem mass spectrometry

HPLC-ELSD: 

high-performance liquid chromatography coupled with evaporative light scattering detection

HPMAE: 

high pressure microwave-assisted extraction

PPD: 

protopanaxadiol

LC-ESI-MS: 

liquid chromatography-electrospray ionization-mass spectrometry

PPT: 

protopanaxatriol

TPNG: 

total Panax notoginsenoside

UPLC/MS: 

ultra performance liquid chromatography mass spectrometry

Declarations

Acknowledgements

The work of LHX is supported by NIH/NHLBI R01 HL97979.

Authors’ Affiliations

(1)
The Ben May Department for Cancer Research, Pritzker School of Medicine, The University of Chicago
(2)
Section of Emergency Medicine, Pritzker School of Medicine, The University of Chicago
(3)
College of Grain Oil and Food Science, Henan University of Technology
(4)
Department of Cell Biol & Mol Med, UMDNJ-New Jersey Medical School
(5)
Department of Biological Sciences, City Colleges of Chicago
(6)
University of Illinois at Chicago
(7)
Shangqiu Medical College

References

  1. Lu JM, Yao Q, Chen C: Ginseng compounds: an update on their molecular mechanisms and medical applications. Curr Vasc Pharmacol. 2009, 7 (3): 293-302.PubMed CentralView ArticlePubMedGoogle Scholar
  2. Peng DC, Chen WP, Xie JT: Antihyperglycemic effects of ginseng and possible mechanisms. Drugs of the future. 2008, 33 (6): 507-514.View ArticleGoogle Scholar
  3. Hofseth LJ, Wargovich MJ: Inflammation, cancer, and targets of ginseng. J Nutr. 2007, 137 (1 Suppl): 183S-185S.PubMedGoogle Scholar
  4. Chevallier A: Encyclopedia of herbal medicine. 2000, New York: DK Publishing IncGoogle Scholar
  5. Blumenthal M, Goldberg A, Brinckmann J: Ginseng root. 2000, Newton, MA: Integrative Medicine CommunicationsGoogle Scholar
  6. Barnes PM, Powell-Griner E, McFann K, Nahin RL: Complementary and alternative medicine use among adults: United States, 2002. Adv Data. 2004, 343: 1-19.PubMedGoogle Scholar
  7. Helms S: Cancer prevention and therapeutics: Panax ginseng. Altern Med Rev. 2004, 9 (3): 259-274.PubMedGoogle Scholar
  8. Hu SY: A contribution to our knowledge of ginseng. Am J Chin Med. 1977, 5 (1): 1-23.View ArticlePubMedGoogle Scholar
  9. Attele AS, Wu JA, Yuan CS: Multiple pharmacological effects of ginseng. Biochem Pharmacol. 1999, 58: 1685-1693.View ArticlePubMedGoogle Scholar
  10. Attele AS, Zhou YP, Xie JT, Wu JA, Zhang L, Dey L, Pugh W, Rue PA, Polonsky KS, Yuan CS: Antidiabetic effects of Panax ginseng berry extract and the identification of an effective component. Diabetes. 2002, 51 (6): 1851-1858.View ArticlePubMedGoogle Scholar
  11. Lee TK, Johnke RM, Allison RR, O'Brien KF, Dobbs LJ: Radioprotective potential of ginseng. Mutagenesis. 2005, 20 (4): 237-243.View ArticlePubMedGoogle Scholar
  12. Xie JT, Mehendale SR, Li X, Quigg R, Wang X, Wang CZ, Wu JA, Aung HH, Rue PA, Bell GI, Yuan CS: Anti-diabetic effect of ginsenoside Re in ob/ob mice. Biochim Biophys Acta. 2005, 1740 (3): 319-325.View ArticlePubMedGoogle Scholar
  13. Wang H, Peng D, Xie J: Ginseng leaf-stem: bioactive constituents and pharmacological functions. Chin Med. 2009, doi:10.1186/1749-8546-4-20Google Scholar
  14. Peng L, Sun S, Xie L-H, Wicks SM, Xie J-T: Ginsenoside Re: Pharmacological Effects on Cardiovascular System. Cardiovascular Therapeutics. 2011,Google Scholar
  15. Lee SJ, Sung JH, Moon CK, Lee BH: Antitumor activity of a novel ginseng saponin metabolite in human pulmonary adenocarcinoma cells resistant to cisplatin. Cancer Lett. 1999, 144 (1): 39-43.View ArticlePubMedGoogle Scholar
  16. Xie JT, Shao ZH, Vanden Hoek TL, Chang WT, Li J, Mehendale S, Wang CZ, Hsu CW, Becker LB, Yin JJ: Antioxidant effects of ginsenoside Re in cardiomyocytes. Eur J Pharmacol. 2006, 532 (3): 201-207.View ArticlePubMedGoogle Scholar
  17. Qi LW, Wang CZ, Yuan CS: American ginseng: potential structure-function relationship in cancer chemoprevention. Biochem Pharmacol. 2010, 80 (7): 947-954.View ArticlePubMedGoogle Scholar
  18. Shi YSC, Zheng B, Li Y, Wang Y: Simultaneous determination of nine ginsenosides in functional foods by high performance liquid chromatography with diode array detector detection. Food Chemistry. 2010, 123: 1322-1327.View ArticleGoogle Scholar
  19. Gillis CN: Panax ginseng pharmacology: a nitric oxide link?. Biochem Pharmacol. 1997, 54 (1): 1-8.View ArticlePubMedGoogle Scholar
  20. Fuzzati N: Analysis methods of ginsenosides. J Chromatogr B Analyt Technol Biomed Life Sci. 2004, 812 (1-2): 119-133.View ArticlePubMedGoogle Scholar
  21. Cheng Y, Shen LH, Zhang JT: Anti-amnestic and anti-aging effects of ginsenoside Rg1 and Rb1 and its mechanism of action. Acta Pharmacol Sin. 2005, 26 (2): 143-149.View ArticlePubMedGoogle Scholar
  22. Xie JT, Wang CZ, Wang AB, Wu J, Basila D, Yuan CS: Antihyperglycemic effects of total ginsenosides from leaves and stem of Panax ginseng. Acta Pharmacol Sin. 2005, 26 (9): 1104-1110.View ArticlePubMedGoogle Scholar
  23. Li X, Sun J, Wang G, Hao H, Liang Y, Zheng Y, Yan B, Sheng L: Simultaneous determination of panax notoginsenoside R1, ginsenoside Rg1, Rd, Re and Rb1 in rat plasma by HPLC/ESI/MS: platform for the pharmacokinetic evaluation of total panax notoginsenoside, a typical kind of multiple constituent traditional Chinese medicine. Biomed Chromatogr. 2007, 21 (7): 735-746.View ArticlePubMedGoogle Scholar
  24. Ota T, Fujikawa-Yamamoto K, Zong ZP, Yamazaki M, Odashima S, Kitagawa I, Abe H, Arichi S: Plant-glycoside modulation of cell surface related to control of differentiation in cultured B16 melanoma cells. Cancer Res. 1987, 47: 3863-3867.PubMedGoogle Scholar
  25. Banthorpe DV: Terpenoids. Natural Products. In. Essex: Longman Scientific and Technical. 1994, 331-339.Google Scholar
  26. Kim YS, Kim DS, Kim SI: Ginsenoside Rh2 and Rh3 induce differentiation of HL-60 cells into granulocytes: modulation of protein kinase C isoforms during differentiation by ginsenoside Rh2. Intl J Biochem Cell Biol. 1998, 30: 327-338.View ArticleGoogle Scholar
  27. Joo KM, Lee JH, Jeon HY, Park CW, Hong DK, Jeong HJ, Lee SJ, Lee SY, Lim KM: Pharmacokinetic study of ginsenoside Re with pure ginsenoside Re and ginseng berry extracts in mouse using ultra performance liquid chromatography/mass spectrometric method. J Pharm Biomed Anal. 2010, 51 (1): 278-283.View ArticlePubMedGoogle Scholar
  28. Peng L, Sun S, Xie L-H, Wicks SM, Xie JT, Ginsenoside Re: Pharmacological effects on cardiovascular system. Cardiovasc Therap. 2011, doi:10.1111/j.1755-5922.2011.00271.xGoogle Scholar
  29. Xie JT, Aung HH, Wu JA, Attele AS, Yuan CS: Effects of American ginseng berry extract on blood glucose levels in ob/ob mice. Am J Chin Med. 2002, 30 (2-3): 187-194.View ArticlePubMedGoogle Scholar
  30. Xie JT, Mehendale SR, Wang A, Aung HH, Wu J, Osinski J, Yuan C-S: American ginseng leaf: Ginsenoside analysis and hypoglycemic activity. Pharmacol Res. 2004, 49: 113-117.View ArticlePubMedGoogle Scholar
  31. Li TSC, Mazza G, Cottrell AC, Gao L: Ginsenosides in roots and leaves of American ginseng. J Agric Food Chem. 1996, 44: 717-720.View ArticleGoogle Scholar
  32. Xie JT, Mehendale SR, Wang A, Han AH, Wu JA, Osinski J, Yuan CS: American ginseng leaf: ginsenoside analysis and hypoglycemic activity. Pharmacol Res. 2004, 49 (2): 113-117.View ArticlePubMedGoogle Scholar
  33. Dharmananda S: The nature of ginseng: traditional use, modern research, and the question of dosage. Herbalgram. 2002, 54: 34-51.Google Scholar
  34. Wang A, Wang CZ, Wu JA, Osinski J, Yuan CS: Determination of major ginsenosides in Panax quinquefolius (American ginseng) using high-performance liquid chromatography. Phytochem Anal. 2005, 16 (4): 272-277.View ArticlePubMedGoogle Scholar
  35. Lim W, Mudge KW, Vermeylen F: Effects of population, age, and cultivation methods on ginsenoside content of wild American ginseng (Panax quinquefolium). J Agric Food Chem. 2005, 53 (22): 8498-8505.View ArticlePubMedGoogle Scholar
  36. Shibata S, Tanaka O, Shoji J, Saito H: Chemistry and pharmacology of Panax. Economic and Medicinal plant Research. 1985, 1: 217-283.Google Scholar
  37. Luchtefeld R, Kostoryz E, Smith RE: Determination of ginsenosides Rb1, Rc, and Re in different dosage forms of ginseng by negative ion electrospray liquid chromatography-mass spectrometry. J Agric Food Chem. 2004, 52 (16): 4953-4956.View ArticlePubMedGoogle Scholar
  38. Xia C, Wang G, Sun J, Hao H, Xiong Y, Gu S, Shang L, Zheng C: Simultaneous determination of ginsenoside Rg1, Re, Rd, Rb1 and ophiopogonin D in rat plasma by liquid chromatography/electrospray ionization mass spectrometric method and its application to pharmacokinetic study of 'SHENMAI' injection. J Chromatogr B Analyt Technol Biomed Life Sci. 2008, 862 (1-2): 72-78.View ArticlePubMedGoogle Scholar
  39. Xie J-T, Attele AS, Yuan C-S: Ginseng: beneficial and potential adverse effect. A textbook of complementary and alternative therapies. Edited by: Yuan C-S, Beiber E, Bauer BA. 2006, Boca Raton, London, New York, Washington, D.C.: CRC Press Company, 71-89.Google Scholar
  40. Kang SY, Schini-Kerth VB, Kim ND: Ginsenosides of the protopanaxatriol group cause endothelium-dependent relaxation in the rat aorta. Life Sciences. 1995, 56 (19): 1577-1586.View ArticlePubMedGoogle Scholar
  41. Zhu GY, Li YW, Hau DK, Jiang ZH, Yu ZL, Fong WF: Protopanaxatriol-type ginsenosides from the root of Panax ginseng. J Agric Food Chem. 2011, 59 (1): 200-205.View ArticlePubMedGoogle Scholar
  42. Mizuno M, Yamada J, Terai H, Kozukue N, Lee YS, Tsuchida H: Differences in immunomodulating effects between wild and cultured Panax ginseng. Biochem Biophys Res Commun. 1994, 200 (3): 1672-1678.View ArticlePubMedGoogle Scholar
  43. Leung KW, Wong AS: Pharmacology of ginsenosides: a literature review. Chin Med. 2010, 5: 20-PubMed CentralView ArticlePubMedGoogle Scholar
  44. Schlag EM, Mclntosh MS: Ginsenoside content and variation among and within American ginseng (Panax quinquefolius L.) populations. Phytochemistry. 2006, 67: 1510-1519.View ArticlePubMedGoogle Scholar
  45. Mihalov JJ, Marderosian AD, Pierce JC: DNA identification of commercial ginseng samples. J Agric Food Chem. 2000, 48 (8): 3744-3752.View ArticlePubMedGoogle Scholar
  46. Qu C, Bai Y, Jin X, Wang Y, Zhang K, You J, Zhang H: Study on ginsenosides in different parts and ages of Panax quinquefolius L. Food Chemistry. 2009, 115: 340-346.View ArticleGoogle Scholar
  47. Wu JM, Lin HY, Zhao LH, Jia HT, Jia HK, Wang Y, Chen DW: Comparative study on quality of Tongrentang red ginseng and Korean red ginseng-determination of ginsenosides and polysaccharides. Zhongguo Zhong Yao Za Zhi. 2007, 32 (7): 573-577.PubMedGoogle Scholar
  48. Sritularak B, Morinaga O, Yuan CS, Shoyama Y, Tanaka H: Quantitative analysis of ginsenosides Rb1, Rg1, and Re in American ginseng berry and flower samples by ELISA using monoclonal antibodies. Nat Med (Tokyo). 2009, 63 (3): 360-363.View ArticleGoogle Scholar
  49. Morinaga O, Uto T, Yuan CS, Tanaka H, Shoyama Y: Evaluation of a new eastern blotting technique for the analysis of ginsenoside Re in American ginseng berry pulp extracts. Fitoterapia. 2009, doi:10.1016/j.fitote.2009.10.005Google Scholar
  50. Lee M-J, Choi J-S, Cha S-W, Lee K-S, Lee Z-W, Hwang G-S, Lee SH, Kamal AHM, Jung Y-A, Seung N-S, Woo S-H: Variation in the ginsenoside profiles of cultivated ginseng (Panax ginseng C.A. Meyer) landraces in Korea. Process Biochemistry. 2011, 46 (1): 258-264.View ArticleGoogle Scholar
  51. Hasegawa H: Proof of the mysterious efficacy of ginseng: basic and clinical trials: metabolic activation of ginsenoside: deglycosylation by intestinal bacteria and esterification with fatty acid. J Pharmacol Sci. 2004, 95 (2): 153-157.View ArticlePubMedGoogle Scholar
  52. Christensen L: Ginsenosides: Chemistry, Biosynthesis, Analysis, and Potential Health Effects. Advances in Food and Nutrition Research. 2008, 55: 1-99.View ArticleGoogle Scholar
  53. Li X, Wang G, Sun J, Hao H, Xiong Y, Yan B, Zheng Y, Sheng L: Pharmacokinetic and absolute bioavailability study of total panax notoginsenoside, a typical multiple constituent traditional chinese medicine (TCM) in rats. Biol Pharm Bull. 2007, 30 (5): 847-851.View ArticlePubMedGoogle Scholar
  54. Qi L-W, Wang C-Z, Yuan C-S: Isolation and analysis if ginseng: advances and challenges. Nat Prod Rep. 2011, DOI: 10.1039/c0np000057dGoogle Scholar
  55. Han BH, Park MH, Han YN, Woo LK, Sankawa U, Yahara S, Tanaka O: Degradation of Ginseng Saponins under Mild Acidic Conditions. Planta Med. 1982, 44 (3): 146-149.View ArticlePubMedGoogle Scholar
  56. Tawab MA, Bahr U, Karas M, Wurglics M, Schubert-Zsilavecz M: Degradation of ginsenosides in humans after oral administration. Drug Metab Despos. 2003, 31: 1065-1071.View ArticleGoogle Scholar
  57. Bae EA, Shin JE, Kim DH: Metabolism of ginsenoside Re by human intestinal microflora and its estrogenic effect. Biol Pharm Bull. 2005, 28 (10): 1903-1908.View ArticlePubMedGoogle Scholar
  58. Chi H, Ji GE: Transformation of Ginsenosides Rb1 and Re from Panax ginseng by Food Microorganisms. Biotechnol Lett. 2005, 27 (11): 765-771.View ArticlePubMedGoogle Scholar
  59. Chen G, Yang M, Guo D: Metabolic study of ginsenoside Re in rats. Zhongguo Zhong Yao Za Zhi. 2009, 34 (12): 1540-1543.PubMedGoogle Scholar
  60. Yang L, Xu S, Liu C, Su Z: In vivo metabolism study of ginsenoside Re in rat using high-performance liquid chromatography coupled with tandem mass spectrometry. Anal Bioanal Chem. 2009, 395: 1441-1453.View ArticlePubMedGoogle Scholar
  61. Liu YM, Yang L, Zeng X, Deng YH, Feng Y, Liang WX: Pharmacokinetics of ginsenosides Rg1 and Re in Shenmai injection. Yao Xue Xue Bao. 2005, 40 (4): 365-368.PubMedGoogle Scholar

Copyright

© Peng et al; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.